What would be your choice of therapy in a fit patient with relapsed CLL previously treated with bendamustine and rituximab who does not want BTK inhibitor therapy?  

Relapsed disease occurred 3.5 years after initial treatment  

Answer from: at Academic Institution

Answer from: Medical Oncologist at Academic Institution
Medical Oncologist at St Louis Cancer Care LLP
As far as PI3K inhibitors are concerned, I believe...
Sign in or Register to read more